NASDAQ · BIVI
BioVie Inc.
$1.38-$0.08 (-5.48%)
BioVie Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.59% below the high.
Loading market information…
OTC · CERO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
CERo Therapeutics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.76% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
CERo Therapeutics Holdings, Inc.’s next earnings report is currently expected on Dec 2, 2026, with estimated earnings per share of -$0.43. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow CERo Therapeutics Holdings, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. This company was founded in 2021 and is headquartered in South San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:52 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | Apr 1, 2025 | -$1.75 | $0.00 |
|---|
| Q3 2024 | Nov 19, 2024 | -$180.00 | $0.00 |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.38-$0.08 (-5.48%)
BioVie Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.59% below the high.
$4.63+$0.81 (+21.05%)
Galmed Pharmaceuticals Ltd.’s quoted price sits in the lower half of its reported 52-week range, 64.92% below the high.
$2.90-$0.03 (-0.86%)
Liminatus Pharma, Inc. Class A Common Stock’s quoted price sits in the lower half of its reported 52-week range, 97.95% below the high.
$2.64+$0.07 (+2.72%)
PMGC Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.82% below the high.
$1.03-$0.02 (-1.9%)
XORTX Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.39% below the high.
$0.01$0.00 (0.0%)
NKGen Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.56% below the high.
$0.65-$0.01 (-1.07%)
Protagenic Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.76% below the high.
$1.37-$0.14 (-9.27%)
Moolec Science S.A.’s quoted price sits in the lower half of its reported 52-week range, 94.1% below the high.
